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Purpose of the study
With NNRTI, the recommended dose of lopinavir/r (LPV/
r) is 4 capsules (533/133 mg) BD. With LPV/r tablets, the
closest doses are 2 tablets (400/100 mg) BD or 3 tablets
[tabs] (600/150 mg) BD. Improved bioavailability of the
tablet suggests that 2 tabs BD should be sufficient, but PK
data are few and generally from Caucasians.
Methods
We conducted a three-period crossover PK study in 40
patients receiving LPV/r tablets with NNRTIs (21 EFV,19
NVP) second-line (first PI) in one Ugandan centre in the
DART trial. Patients on 3 tabs BD underwent 6-point PK
sampling (0, 2, 4, 6, 8 and 12 hours) after observed intake
with a standardised breakfast. They then switched to 4
caps BD for 2 weeks before a second PK, then switched to
2 tabs BD for 2 weeks before a third PK, after which they
returned to 3 tabs BD. Analysis excluded two patients with
minimal LPV/r exposure on 4 caps BD.
Summary of results
6/20 EFV and 13/18 NVP patients included were female
(reflecting contra-indication of EFV in women with child-
bearing potential), with median age 41 and 35 years, and
weight 60 and 64 kg, respectively. On EFV, mean (SD)
LPV AUC was 104 (54), 70 (27) and 63 (33) ug.h/l on 3
tabs BD, 4 caps BD, and 2 tabs BD, respectively, with cor-
responding GMR vs. 4 caps BD 1.40 (90% CI 1.18–1.65,
p = 0.002) and 0.82 (0.68–0.99, p = 0.09). On NVP, mean
(SD) LPV AUC was 118 (33), 77 (39) and 69 (34) ug.h/l,
respectively, with corresponding GMR vs. 4 caps BD 1.66
(1.46–1.88, p < 0.001) and 0.90 (0.77–1.06, p = 0.27) for
3 and 2 tabs BD, respectively. On EFV, 15%/15%/40%
had C12(trough) <1 ug/ml (p = 0.1) with corresponding
GMR vs. 4 caps BD 1.48 (1.09–2.02, p = 0.04) and 0.62
(0.39–0.98, p = 0.08) for 3 and 2 tabs BD, respectively. On
NVP, 0%/22%/28% had C12 <1 ug/ml (p = 0.06) with
corresponding GMR vs. 4 caps BD 2.31 (1.64–3.24, p <
0.001) and 0.80 (0.57–1.12, p = 0.26) for 3 and 2 tabs BD,
respectively. However, 40%/5%/15% EFV and 56%/28%/
17% NVP patients had C12 >5 ug/ml. There was no effect
of sex, age, weight or BMI on AUC or C12.
Conclusion
When co-administered with NVP or EFV in African
patients, LPV AUC and C12 are higher with 3 tablets BD
and lower with 2 tablets BD compared to 4 capsules BD.
Higher plasma levels on 3 tablets BD may lead to greater
long-term toxicity, whereas low plasma C12 on 2 tablets
BD may increase the risk of virological failure. However,
AUC on 4 caps BD was lower than expected, and tablet
AUC variability was higher than expected. Further PK
sampling is therefore ongoing to estimate PK parameters
in African patients taking 2 LPV/r tablets BD without
NNRTIs.
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